COMP <GO>
CAI vs MRK // PIOTROSKI F-SCORE QUALITY
Caris Life Sciences Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: CAI 4
— MRK 10
▲ PIOTROSKI F-SCORE QUALITY LEADER: CAI
LAST: $34.33 (-5.01%) • MKT CAP: $10.21B
piotroski-score
8/9
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
piotroski-score
7/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CAI VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CAI | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.40% | 20.70% | -16.30 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 15.3x | +79.70 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 0.65% | 3.42% | -2.77 | MRK | /fcf-yield <GO> |
| Operating Margin | 5.60% | 34.30% | -28.70 | MRK | /operating-margins <GO> |
| Net Profit Margin | -8.40% | 28.10% | -36.50 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 97.00% | 1.30% | +95.70 | CAI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.79 | 5.19 | +4.60 | CAI | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 8/9 | 7/9 | +1.00 | CAI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.60% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.8 | 56.9 | +5.92 | CAI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 0.92 | -0.01 | MRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 18.4x | +2.60 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.21B | $361.02B | -$350.81B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CAI REV | MRK REV | CAI GROSS % | MRK GROSS % | CAI FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $812.0M | $65.01B | 44.0% | 74.8% | $66.9M | $12.36B |
| FY 2024 | $412.3M | $64.17B | 44.0% | 76.3% | -$253.6M | $18.10B |
| FY 2023 | $306.1M | $60.12B | 44.0% | 44.0% | -$289.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CAI // BETA 0.91
MRK // BETA 0.92